Dr. Esperanza Papadopoulos, MD

Dr. Papadopoulos practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Papadopoulos' NPI, 1851362685, was assigned on January 30, 2006. Dr. Papadopoulos graduated from New York University School of Medicine in 1982. Dr. Papadopoulos holds New York license 155800.

Dr. Papadopoulos' primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Papadopoulos' primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Papadopoulos to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Papadopoulos practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Papadopoulos' primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Papadopoulos is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Papadopoulos' licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists anemia among the conditions Dr. Papadopoulos treats.

CMS data shows 335 Medicare services from Dr. Papadopoulos across 3 procedure codes in 2024, for 59 Medicare patients. Medicare paid $39,438 for them.

CMS counts 59 Medicare patients who saw Dr. Papadopoulos in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have high cholesterol, and 73% have high blood pressure. Their average risk score is 3.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Papadopoulos' median patient age at 68, with 52% women.

In 2024, Dr. Papadopoulos wrote 718 Medicare Part D claims for 42 patients. 92% of them were for generic drugs. CMS names the drug for 519 of them, across 21 drugs with 11 or more claims each, at $613,758 in total drug cost. In 2023, CMS named 439 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Papadopoulos for performance year 2024, reported as part of a group. Dr. Papadopoulos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Papadopoulos as offering telehealth.

Dmand AI links 161 papers to Dr. Papadopoulos, published from 2003 to 2025. 2017 was the busiest year, with 16. The most frequent topics are Hematopoietic Stem Cell Transplantation, Transplantation, Homologous and Graft vs Host Disease. Dr. Papadopoulos has published most often in Biol Blood Marrow Transplant. Dr. Papadopoulos' most frequent co-authors are Ann A. Jakubowski, MD, Sergio A. Giralt, MD and Miguel A. Perales, MD.

Dmand AI links Dr. Papadopoulos to 1 clinical trial. Conditions studied include Intraocular Lymphoma and Dendritic Cell Sarcoma, Interdigitating.

CMS Open Payments shows 3 general payments to Dr. Papadopoulos from 3 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 85% of the total. Incyte Corporation paid the most, $125. It also lists 1 research payment totaling $1,488 in 2017.

Dr. Papadopoulos graduated from New York University School of Medicine in 1982.

Dr. Papadopoulos is in network with 12 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.